Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN 10
- Sponsors Novo Nordisk
- 28 Jun 2017 Planned End Date changed from 12 Aug 2018 to 14 Aug 2018.
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.
- 09 May 2017 New trial record